A 2018 systematic meta-analysis in the Journal of Aging Research (Gorouhi & Maibach) reviewed controlled clinical trials of topical formulations for facial aging. Across studies, consistently demonstrated.
Injectable in clinical practice (mesotherapy protocols) has shown faster, more robust results than topical alone, consistent with superior bioavailability.
(, tetrapeptide Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed by Vladimir Khavinson, MD, PhD, at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1980s. It is derived from a larger peptide — epithalamin — extracted from the bovine pineal gland, and its development was driven by observations that pineal gland peptides appeared to extend lifespan and maintain thymic function in aging animals.
's most striking proposed mechanism is activation of telomerase — the enzyme responsible for maintaining the length of telomeres (the protective caps on chromosomal ends that shorten with each cell division). Telomere shortening is one of the hallmarks of cellular aging identified by López-Otín et al. in their landmark 2013 Cell review "The Hallmarks of Aging."
A 2003 study by Khavinson et al. published in Neuroendocrinology Letters demonstrated that treatment in cultured human fetal fibroblasts increased telomere length and extended cellular replicative potential beyond what was observed in untreated controls. This was attributed to telomerase induction.
Additionally, Khavinson's group published a 15-year follow-up study on elderly patients in St. Petersburg who received periodic Epithalamin/ treatment. The treated cohort demonstrated 27–33% lower mortality over the study period versus matched controls, along with preserved immune function and reduced cardiovascular events. This data, while requiring replication in large Western RCTs, represents the most extensive longitudinal human data available on any peptide for longevity.
Synthetic HGH has been prescribed off-label for anti-aging purposes since the early 1990s, popularized partly by the 1990 New England Journal of Medicine study by Rudman et al. showing improvements in lean body mass and skin thickness with HGH injection in elderly men. However, subsequent evidence revealed significant concerns: elevated IGF-1 from exogenous HGH may accelerate cancer riskand the acromegaly-like side effects (joint pain, carpal tunnel, fluid retention) are common at supraphysiologic doses.
does not directly elevate IGF-1 or GH in a supraphysiologic fashion. It appears to work through upstream regulatory pathways — normalizing circadian melatonin secretion, restoring thymic peptide output, and activating telomerase — that support physiologic regeneration without the risk profile of exogenous HGH. For this reason, longevity clinicians often prefer as part of an anti-aging stack over direct GH supplementation.
Thymosin Beta-4 (Tβ4) is a 43-amino-acid peptide produced primarily in the thymus and found in high concentrations at sites of tissue injury. It plays a central role in actin polymerization — a process essential to cell migration, wound repair, and tissue remodeling. In skin, Tβ4 accelerates keratinocyte and fibroblast migration to wound sites, accelerating closure and improving scar quality.
Key evidence includes.
In systemic longevity protocols, Tβ4 is often included alongside and in recovery support stacks aimed at recovering from training stress, surgery, or cumulative oxidative damage.
(Body Protective Compound-157) is a 15-amino-acid peptide derived from a protein found in gastric juice. Originally studied for gastrointestinal repair, it has expanded into one of the most widely used research peptides in longevity and regenerative medicine.
Relevant to skin and anti-aging.
Delivery method is often the decisive factor in peptide efficacy. Topical peptide products face a fundamental barrier: the skin's stratum corneum actively blocks macromolecules above approximately 500 daltons. Many peptides exceed this threshold, meaning topical formulations with unmodified peptides have limited dermal penetration.
Strategies that improve topical delivery include.
Injectable peptides (subcutaneous or intramuscular) bypass the skin barrier entirely and achieve systemic bioavailability. Mesotherapy protocols deliver peptides directly to the dermis. For anti-aging purposes, injected peptides — particularly (typically cycled at 5–10 mg/day for 10–20 days, 1–2 times per year) and systemic
Many longevity-focused practitioners use peptides in combination, reasoning that they address distinct but complementary mechanisms.
It is important to note that the combined use of peptides in longevity protocols is largely informed by mechanism-based reasoning and case experience rather than large randomized trials. This is an evolving field, and any peptide protocol should be supervised by a knowledgeable clinician who can monitor for adverse effects and adjust based on individual response.
Peptides are not a replacement for foundational health behaviors — sun protection, quality sleep, nutrition, and exercise. They are best understood as targeted biological amplifiers that support the body's own regenerative capacity. Patients using evidence-based peptides under clinical supervision typically report.
Our providers design evidence-informed peptide protocols tailored to your age, goals, and health history — with monitoring included. Start a consultation to learn what may be right for you.
Start Your Consultation